WuXi Biologics (Cayman) Inc. (WXIBF)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Ge Li Ph.D. | Founder & Chairman | -- | -- | 1967 |
| Dr. Zhisheng Chen Ph.D. | CEO & Executive Director | 1.18k | -- | 1973 |
| Mr. Ming Tu | CFO & Executive VP | -- | -- | 1969 |
| Lihua Yu M.B.A. | COO & Senior VP | -- | -- | -- |
| Dr. Jijie Gu Ph.D. | Chief Scientific Officer & President of Global Biologics Research | -- | -- | 1966 |
| Ms. Lina Fan Ph.D. | Senior VP & Head of Investor Relations | -- | -- | -- |
| He Wang | General Counsel, Chief Compliance Officer, SVP and Head of Legal,Compliance & Risk Management Center | -- | -- | -- |
| Ms. Li Xiong | VP & Head of Global Human Resources | -- | -- | -- |
| Mr. Jian Dong | CEO of WuXi Vaccines | -- | -- | 1964 |
| Mr. Angus Scott Marshall Turner M.B.A. | Senior VP and Head of Global BD & Alliance Management | -- | -- | 1968 |
WuXi Biologics (Cayman) Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 12,575
Description
WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People's Republic of China, North America, Europe, Singapore, Japan, South Korea, and Australia. It operates through two segments: Biologics and XDC. The company provides a suite of solutions for biologic discovery, from concept to IND, that seamlessly transits to CMC and downstream process development through its contract research, development, and manufacturing organization platforms, including WuXiBody, SDArBodY, T cell engager, Single B Cell Cloning Technology, WuXia, WuXiUP, WuXiUI, and WuXiHigh. It engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, production and sales of medicals, and biologics clinical and manufacturing services; production and sale of medicals; vaccine contract development and manufacturing organization (CDMO) and related business; and engages in investment and material supplier activities. It has a research service agreement with BioNTech SE to discover and investigate monoclonal antibodies for developing next-generation therapeutic product candidates. The company was incorporated in 2014 and is headquartered in Wuxi, China.
Corporate Governance
Upcoming Events
August 19, 2025 at 10:59 AM UTC - August 25, 2025 at 12:00 PM UTC
WuXi Biologics (Cayman) Inc. Earnings Date
Recent Events
Recent Events Information Not Available